|
|
Protagonist Therapeutics inc (PTGX) |
|
Price: $46.2000
$-0.82 
-1.744%
|
| Day's High:
| $48
| Week Perf:
| 2.85 %
|
| Day's Low: |
$ 45.50 |
30 Day Perf: |
13.82 % |
| Volume (M): |
699 |
52 Wk High: |
$ 48.00 |
| Volume (M$): |
$ 32,312 |
52 Wk Avg: |
$27.52 |
| Open: |
$47.17 |
52 Wk Low: |
$13.72 |
|
|
| Market Capitalization (Millions $) |
2,832 |
| Shares
Outstanding (Millions) |
61 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
319 |
| Net Income (TTM) (Millions $) |
170 |
| Cash Flow (TTM) (Millions $) |
120 |
| Capital Exp. (TTM) (Millions $) |
1 |
Protagonist Therapeutics Inc
Protagonist Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on the development of peptide-based drugs. The company's primary goal is to discover and develop innovative treatments for gastrointestinal diseases and disorders.
Protagonist Therapeutics utilizes its proprietary technology platform called Protagonist Integrative Peptide Therapeutics (IPT) to identify and optimize peptides that can target specific disease pathways. The IPT platform combines computational modeling, synthetic chemistry, and biology to design and develop these peptide-based drugs.
The company's pipeline includes various drug candidates at different stages of development, targeting different indications such as inflammatory bowel disease, gastrointestinal cancers, and polycystic kidney disease. Protagonist Therapeutics aims to address unmet medical needs and provide novel treatment options for patients in these therapeutic areas.
With a focus on advancing its drug candidates through clinical trials and securing regulatory approvals, Protagonist Therapeutics aims to become a leading company in the field of peptide-based therapeutics. The company collaborates with pharmaceutical companies and research institutions to accelerate the development of its drug candidates and expand its pipeline.
Company Address: 7707 Gateway Boulevard, Suite 140 Newark 94560 CA
Company Phone Number: 474-0170 Stock Exchange / Ticker: NASDAQ PTGX
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Protagonist Therapeutics Inc
Protagonist Therapeutics Inc, a biopharmaceutical company specializing in the development of peptide-based therapies, has reported impressive financial results for the first quarter of 2024. With revenues reaching $254.953 million, the company has achieved substantial growth compared to the same period last year. Moreover, the net earnings for the first quarter of 2024 amounted to $207.340 million, marking a significant improvement from a net loss of $33.725 million in the previous year.
One of the highlights of Protagonist Therapeutics' financial performance is the improvement in its profit margins. The net margin for the first quarter of 2024 rose to an impressive 81.32%, indicating the company's ability to generate substantial profits from its operations. Additionally, the operating margin edged up to 80.92%, reflecting the efficiency and profitability of the company's core business.
|
| Protagonist Therapeutics Inc
Protagonist Therapeutics Inc. (PTGX) has showcased strong performance in recent trading days, with a solid gain of 8.45%. This surge in stock price has brought the share value to 26.09% during the first quarter of 2024. PTGX stock is currently on an upward trajectory and is only 1.9% away from its 52-week high of $30.1.
One of the main contributing factors to PTGX's success is its impressive financial results. As revealed by the company, in the fiscal time-frame of October to December 31, 2023, Protagonist Therapeutics Inc. achieved a remarkable revenue of $60 million. This represents a significant improvement compared to the same quarter the previous year when the company experienced a net loss of -$34.194 million.
|
| Protagonist Therapeutics Inc
The Major Pharmaceutical Preparations sector has been dominated by industry leaders, while some lesser-known companies have remained somewhat overlooked. Among them is Protagonist Therapeutics Inc (PTGX), an evolving entity that recently disclosed its third-quarter financial results for 2023. Despite trailing behind the sector leaders, these results offer valuable insights into the company's current performance and its potential impact on the company's future trajectory.
Operating Deficit Trends:
In the third quarter of 2023, PTGX reported an operating deficit of $-38.326 million. To put this figure into context, it's important to analyze the company's performance in the same period of the previous year. During Q3 2022, PTGX recorded an operating deficit of $-32.303 million. This data suggests that the company's financial situation worsened, as the operating deficit increased by approximately $6 million.
|
| Protagonist Therapeutics Inc
Protagonist Therapeutics Inc (PTGX) has recently released its financial results for the April to June 30, 2023 fiscal span, and while the numbers may not be impressive at first glance, there are underlying factors that suggest a potential turnaround for the company. Despite a loss per share of $-0.68, an improvement from $-0.84 compared to the previous year, and an increased shortfall from the prior financial reporting period, there are reasons to remain bullish about PTGX.
One notable aspect of the financial report is the consistent revenue of $0.00 million, which remained unchanged from the previous year. While this may seem discouraging, it is essential to note that there has been no significant drop, especially considering the challenging economic conditions of the past year. In fact, the consecutive revenue stability could indicate that PTGX has reached a bottom and is poised for growth in the coming quarters.
|
| Protagonist Therapeutics Inc
Protagonist Therapeutics Inc is a biopharmaceutical company that specializes in developing peptide-based drugs to treat various diseases. The company's objective is to leverage its proprietary technology platform to create novel and targeted therapeutics that can improve outcomes for patients suffering from a wide range of medical conditions, including gastrointestinal-related issues, autoimmune disorders, and certain types of cancer.
Unfortunately, the company's financial performance for the fiscal year ending March 31, 2023, did not meet expectations. The company's diminishing returns grew to $-0.67 per share, compared to $-0.43 per share the previous year. However, the EPS improved from $-0.69 per share from the previous reporting period. Furthermore, the revenue remained unchanged at $0.00 million from $25.72 million in the corresponding reporting period a year before, and sequentially from $0.00 million.
|
| Per Share |
Current |
| Earnings (TTM) |
2.57 $ |
| Revenues (TTM) |
5.21 $
|
| Cash Flow (TTM) |
1.96 $ |
| Cash |
9.2 $
|
| Book Value |
8.83 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
2.57 $
|
| Revenues (TTM) |
5.21 $ |
| Cash Flow (TTM) |
1.96 $ |
| Cash |
9.2 $
|
| Book Value |
8.83 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
